Tag Archives: variants

Omicron subvariants “of concern” drive surge in cases and reinfection rates

Photo courtesy of the National Institute of Infectious Diseases.

The COVID-19 story of the summer is omicron subvariants.

As of mid-July, two subvariants are “of concern,” according to the CDC: BA.4 and BA.5, which make up about 80% all COVID-19 cases in the U.S. Another variant, though it has yet to reach the status of “concern,” is BA.2.75, which is rapidly spreading in India and could become a threat in the U.S., according to virologists. (Omicron is the SARS-CoV-2 variant that emerged and swept the globe beginning November 2021, causing a big wave in cases, hospitalizations and deaths globally.)

How much the public should worry about these variants is a matter of debate among public health experts. See this July 13 story in Business Insider, quoting four infectious disease experts I have contacted frequently over the past two and half years. Three of the four experts (Amesh Adalja, M.D., Celine Gounder, M.D., Katelyn Jetelina, Ph.D., M.P.H., and Preeti Malani, M.D.) ranked the risks — on a scale of 1 to 10 — of between 0 and 7 depending upon age, health status and geographic location. One wouldn’t rank the risk because the data isn’t clear.

Some researchers, including Eric Topol, M.D., are extremely concerned because the variant is so contagious.

Continue reading

Resources for covering the COVID-19 and variants story

There is a growing amount of concern in the U.S. about SARS-CoV-2 variants and the possibility they may diminish the effectiveness of COVID-19 vaccines.

The story is evolving. On Jan. 25, the Minnesota Department of Health said a variant, first found in Brazil, was found in a patient in Minnesota. On Jan. 28, the CDC announced that a variant, first found in South Africa, was found in South Carolina.  Both variants have shown a potential to reduce vaccine effectiveness. [See this piece by AHCJ’s Tara Haelle on understanding the nuances of vaccine efficacy.] Continue reading